Adam Fundytus

ORCID: 0000-0001-9119-9710
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Economic and Financial Impacts of Cancer
  • Health Systems, Economic Evaluations, Quality of Life
  • Advances in Oncology and Radiotherapy
  • Global Cancer Incidence and Screening
  • Pharmaceutical Economics and Policy
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Screening and Detection
  • Venous Thromboembolism Diagnosis and Management
  • Statistical Methods in Clinical Trials
  • Lung Cancer Treatments and Mutations
  • Pancreatic and Hepatic Oncology Research
  • Acute Lymphoblastic Leukemia research
  • Cancer Immunotherapy and Biomarkers
  • BRCA gene mutations in cancer
  • Innovations in Medical Education
  • Cancer Genomics and Diagnostics
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Ethics in Clinical Research
  • Cancer and Skin Lesions
  • Childhood Cancer Survivors' Quality of Life
  • Cardiac pacing and defibrillation studies
  • Pharmaceutical industry and healthcare
  • Biomedical Ethics and Regulation
  • Biosimilars and Bioanalytical Methods
  • Ultrasound in Clinical Applications

BC Cancer Agency
2023-2025

Queen's University
2017-2022

Kingston General Hospital
2017-2021

University of Calgary
2010-2019

King's College London
2017

Kings Health Partners
2017

Libin Cardiovascular Institute of Alberta
2010

The WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. We aimed investigate whether in aligned with frontline oncologists worldwide, and extent which these accessible routine clinical practice.This international, cross-sectional survey was developed by investigators from a range practice settings across low-income high-income countries, including members Cancer...

10.1016/s1470-2045(21)00463-0 article EN cc-by The Lancet Oncology 2021-09-21

To our knowledge, there is no literature that has described medical oncology (MO) workload in the global context. Here, we report results of an international study MO workload.An online survey was distributed through a snowball method via national societies to chemotherapy-prescribing physicians 65 countries. Countries were classified into low- or low-middle-income countries (LMICs), upper-middle-income (UMICs), and high-income (HICs) on basis World Bank criteria. Workload measured as annual...

10.1200/jgo.17.00126 article EN cc-by-nc-nd Journal of Global Oncology 2017-12-15

While the burden of cancer in Africa is rapidly rising, there a lack investment healthcare professionals to deliver care. Here we report results survey systemic therapy workload oncologists comparison other countries.An online was distributed through snowball method via national oncology societies chemotherapy-prescribing physicians 65 countries. The within network associated with African Organisation for Research and Training Cancer (AORTIC). Workload measured as annual number new patient...

10.1186/s13027-019-0227-8 article EN cc-by Infectious Agents and Cancer 2019-05-20

Background: Understanding oncology health human resources across Canada is critical to the delivery of quality cancer care. Little has been published about medical (MO) workforce and trainees; this study sought characterize trends in MO explore relationship between oncologists incidence as a surrogate demand marker. Materials Methods: Publicly available databases from Canadian Medical Association, Institute Health Information, Post MD Education Registry were utilized estimate number,...

10.3390/curroncol32020070 article EN cc-by Current Oncology 2025-01-28

62 Background: Use of PARP inhibitors (PARPi) improves outcomes in patients with metastatic castrate-resistant prostate cancer (mCRPC) harboring germline or somatic homologous recombination repair (HRR) mutations. To ensure timely PARPi initiation, genetic results should be available at castrate resistance, testing initiated the castration-sensitive (mCSPC) setting. Relying on ad hoc, provider-initiated risks biomarker unavailability when treatment decisions are made, leading to suboptimal...

10.1200/jco.2025.43.5_suppl.62 article EN Journal of Clinical Oncology 2025-02-10

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...

10.1001/jamaoncol.2021.3600 article EN JAMA Oncology 2021-08-26

Highlight the challenges associated with managing breast cancer in female-to-male (FtM) transgender individuals. This is a rare entity, requiring nuanced decision-making regarding surgery as well adjuvant therapies given unique hormonal environment seen individuals taking exogenous androgen part of their gender identity. Contemporary case report derived from our clinical experience. Discussion focuses on brief summation all known cases FtM described literature. A 48-year-old individual...

10.1111/tbj.13655 article EN The Breast Journal 2019-11-20

Abstract Background: The growing burden of cancer within India has implications across the health system including operational delivery care and planning for human resources. Here, we report Indian results a global survey medical oncology (MO) workload in comparison to oncologists (MOs) other low-middle- income countries (LMICs). Methods: An online was distributed through snowball method national societies chemotherapy-prescribing physicians 22 LMICs. MOs by Society Medical Pediatric...

10.4103/ijmpo.ijmpo_66_18 article EN cc-by-nc-nd Indian Journal of Medical and Paediatric Oncology 2019-01-01

Oncology randomized controlled trials (RCTs) are increasingly global in scope. Whether authorship is equitably shared between investigators from high-income countries (HIC) and low-middle/upper-middle incomes (LMIC/UMIC) not well described. The authors conducted this study to understand the allocation of patient enrollment across all oncology RCTs globally.A cross-sectional retrospective cohort phase 3 (published 2014-2017) that were led by HIC recruited patients LMIC/UMIC.During 2014-2017,...

10.1002/cncr.34919 article EN cc-by-nc Cancer 2023-06-29

Access to essential cancer medicines is a major determinant of childhood outcomes globally. The degree which pediatric oncologists deem listed on WHO's Model List Essential Medicines for Children (EMLc) unknown, as the extent such are accessible front lines clinical care.An electronic survey developed was distributed through International Society Pediatric Oncology mailing list members from 87 countries. Respondents were asked select 10 that would provide greatest benefit patients in their...

10.1200/go.22.00034 article EN JCO Global Oncology 2022-06-01

The WHO essential medicines list (EML) guides selection of drugs for national formularies. Here, we evaluate which are considered highest priority by Indian oncologists and the extent to they available in routine practice.This is a secondary analysis an electronic survey developed EML Cancer Medicine Working Group. was distributed globally using hierarchical snowball method physicians who prescribe systemic anticancer therapy. captured 10 population health their availability practice.The...

10.1200/go.22.00060 article EN cc-by-nc-nd JCO Global Oncology 2022-07-01

Background: In 2000, a Canadian task force recommended that medical oncologists (MOS) meet target of 160–175 new patient consultations per year. Here, we report the results global survey mo workload compared with in other high-income countries (HICS). Methods: Using snowball method, an online was distributed by national oncology societies to chemotherapy-prescribing physicians 22 HICS (World Bank criteria). The within Canada all members Association Medical Oncologists. Workload measured as...

10.3747/co.25.3999 article EN cc-by Current Oncology 2018-06-01

e13526 Background: It is unclear whether the Canadian medical oncology workforce has kept pace with country’s rising cancer incidence over last three decades. This study sought to characterize national and provincial trends in oncologist (MO) MO trainee during 27 years explore relationship between incidence. Methods: Publicly available databases from Medical Association (CMA; 1994-2019) Institute of Health Information (CIHI) database (1994-2020) were utilized estimate number, demographics,...

10.1200/jco.2022.40.16_suppl.e13526 article EN Journal of Clinical Oncology 2022-06-01

Superior vena cava (SVC) syndrome is classically thought of as a complication malignancy.However, SVC secondary to indwelling central venous catheters (CVC) another important entity.Amongst those with CVCs who develop syndrome, the majority are attributed thrombosis.Aside from thrombosis, can lead mechanical obstruction blood flow in an already narrowed vessel.We present first case hyperacute that developed within 6 hours insertion CVC into patient's right internal jugular vein alongside...

10.5005/jp-journals-10071-23140 article EN Indian Journal of Critical Care Medicine 2019-01-01

e18080 Background: With a disproportionate global burden of cancer, access to care in low-middle income countries (LMICs) is pressing issue. To our knowledge there no literature that has described medical oncology (MO) workload the context. Here, we report first results an international study MO training, infrastructure and workload. Methods: A multinational panel oncologists from diverse practice settings designed 51 item online survey. The survey was distributed through snowball method via...

10.1200/jco.2017.35.15_suppl.e18080 article EN Journal of Clinical Oncology 2017-05-20

Use of value framework thresholds in the design clinical trials may increase proportion randomized controlled that identify clinically meaningful advances for patients. Existing frameworks have not been applied to research output a cooperative cancer group. We apply trial Canadian Cancer Trials Group (CCTG).Statistical design, study characteristics, and results all published phase III CCTG were abstracted. European Society Medical Oncology-Magnitude Clinical Benefit Scale (ESMO-MCBS)...

10.1093/jnci/djab051 article EN JNCI Journal of the National Cancer Institute 2021-03-23
Coming Soon ...